ホームRGEDF • OTCMKTS
add
Gedeon Richter Ord Shs
市場ニュース
財務情報
損益計算書
収益
純利益
| (HUF) | 2024年9月info | 前年比変化率 |
|---|---|---|
収益 | 2167.30億 | 14.95% |
営業費用 | 946.86億 | 10.59% |
純利益 | 370.60億 | -32.07% |
純利益率 | 17.10 | -40.89% |
1 株当たりの収益 | — | — |
EBITDA | 763.89億 | 23.89% |
実効税率 | 19.13% | — |
貸借対照表
総資産
負債総額
| (HUF) | 2024年9月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 749.87億 | -29.24% |
総資産 | 1.49兆 | 9.53% |
負債総額 | 2588.34億 | -1.37% |
純資産 | 1.23兆 | — |
発行済み株式 | 1.83億 | — |
帳簿価格 | 0.00 | — |
総資産利益率 | 10.29% | — |
資本利益率 | 11.59% | — |
キャッシュ フロー
現金の純増減額
| (HUF) | 2024年9月info | 前年比変化率 |
|---|---|---|
純利益 | 370.60億 | -32.07% |
営業キャッシュ フロー | 675.52億 | 56.30% |
投資キャッシュ フロー | -136.88億 | 54.12% |
財務キャッシュ フロー | -366.96億 | -409.23% |
現金の純増減額 | 171.18億 | -34.71% |
フリー キャッシュ フロー | 131.87億 | 1,594.12% |
概要
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest. It is the largest pharmaceutical company in Central and Eastern Europe, with an expanding direct presence in Western Europe, China, Northern America and Latin America. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.
Gedeon Richter Plc. has a primary listing on the Budapest Stock Exchange and is a constituent of the BUX Index. It had a market capitalisation of approximately $6.6 billion as of 2018, the third largest of companies with a primary listing on the Budapest Stock Exchange. It has secondary listings on the Luxembourg Stock Exchange.
Richter sells products for the central nervous system, women's health and cardiovascular therapeutic areas among others. The company is also active in biosimilar product development. The company was established in Budapest by Gedeon Richter, a pharmacist, in 1901. Wikipedia
CEO
設立
1901
ウェブサイト
従業員数
11,603
